MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 279.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,699 shares of the company’s stock after acquiring an additional 7,879 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Telomir Pharmaceuticals were worth $44,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Rhumbline Advisers increased its holdings in Telomir Pharmaceuticals by 105.9% during the 4th quarter. Rhumbline Advisers now owns 8,600 shares of the company’s stock valued at $35,000 after acquiring an additional 4,424 shares in the last quarter. Virtu Financial LLC purchased a new position in Telomir Pharmaceuticals during the 4th quarter valued at about $62,000. JPMorgan Chase & Co. increased its holdings in Telomir Pharmaceuticals by 1,096.4% during the 4th quarter. JPMorgan Chase & Co. now owns 41,444 shares of the company’s stock valued at $171,000 after acquiring an additional 37,980 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Telomir Pharmaceuticals by 327.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 46,406 shares of the company’s stock valued at $191,000 after acquiring an additional 35,556 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Telomir Pharmaceuticals by 73.3% during the 4th quarter. Geode Capital Management LLC now owns 413,677 shares of the company’s stock valued at $1,705,000 after acquiring an additional 174,940 shares in the last quarter.

Telomir Pharmaceuticals Price Performance

Shares of NASDAQ TELO opened at $2.10 on Tuesday. The company has a 50-day simple moving average of $2.58 and a 200-day simple moving average of $3.85. Telomir Pharmaceuticals, Inc. has a 12 month low of $1.88 and a 12 month high of $8.40. The company has a market cap of $62.50 million, a PE ratio of -3.62 and a beta of 0.17.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its earnings results on Monday, May 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. On average, analysts anticipate that Telomir Pharmaceuticals, Inc. will post -0.4 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on TELO shares. RODMAN&RENSHAW upgraded shares of Telomir Pharmaceuticals to a “strong-buy” rating in a report on Thursday, February 20th. Rodman & Renshaw started coverage on shares of Telomir Pharmaceuticals in a report on Friday, February 21st. They set a “buy” rating and a $15.00 price target for the company.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.